Public Market Listing
688331 SSE
SSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (6 total) 6 Total Assets
0 Approved
4 Phase 3 / Filed
2 Phase 1–2 / Early
10 Diseases
Disease: All diseases (6) Non-Small Cell Lung Cancer (4) Breast Cancer (1) Gastric Cancer (1) Bladder / Urothelial Cancer (1) Age-Related Macular Degeneration (1) Diabetic Macular Edema (1) Rheumatoid Arthritis (1) IgA Nephropathy (1) Sjögren's Disease (1) Myasthenia Gravis (1)
Stage: All stages (6) Approved / Phase 4 (0) Phase 3 / Filed (4) Phase 2 Phase 1 / Preclinical
Quick filter: All (6) Non-Small Cell Lung Cancer (4) Breast Cancer (1) Gastric Cancer (1) Bladder / Urothelial Cancer (1) Age-Related Macular Degeneration (1)
Showing 6 of 6 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 HER2 Antibody–drug conjugate
Non-Small Cell Lung Cancer Breast Cancer Gastric Cancer Bladder / Urothelial Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer, Urothelial Carcinoma Phase 3 PD-1 + VEGF Multispecific antibody
Non-Small Cell Lung Cancer
Phase 3 VEGF-A / FGF-2 (dual blockade) Protein / enzyme therapeutic
Age-Related Macular Degeneration Diabetic Macular Edema
Phase 3 BAFF / APRIL Protein / enzyme therapeutic
Rheumatoid Arthritis IgA Nephropathy Sjögren's Disease Myasthenia Gravis
Generalized Myasthenia Gravis Phase 2 MET Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1 IL-15 receptor Protein / enzyme therapeutic
Non-Small Cell Lung Cancer
Upcoming events (24 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (4) December 2026 (4) Disitamab Vedotin Phase 2/3 Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Est. primary completion 2026-12 ·
NCT06221748 ·
CT.gov ↗ What to watch
Disitamab Vedotin Phase 3 Urothelial Carcinoma, HER2-expressing Est. primary completion 2026-12-31 ·
NCT05302284 ·
CT.gov ↗ What to watch
Telitacicept Phase 3 Myasthenia Gravis, Ocular Est. primary completion 2026-12-31 ·
NCT07249632 ·
CT.gov ↗ What to watch
2027 (9) January 2027 (1) March 2027 (1) Telitacicept Phase 3 Generalized Myasthenia Gravis Est. primary completion 2027-03 ·
NCT06456580 ·
CT.gov ↗ What to watch
May 2027 (1) RC148 Phase 2/3 Colorectal (Colon or Rectal) Cancer Est. primary completion 2027-05-12 ·
NCT07462143 ·
CT.gov ↗ What to watch
June 2027 (1) October 2027 (1) Disitamab Vedotin Phase 1/2 Breast Cancer, Breast Neoplasms Est. primary completion 2027-10-25 ·
NCT06966453 ·
CT.gov ↗ What to watch
December 2027 (4) RC148 Phase 2 Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by H … Est. primary completion 2027-12 ·
NCT07874282 ·
CT.gov ↗ What to watch
RC148 Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2027-12-31 ·
NCT07416474 ·
CT.gov ↗ What to watch
2028 (4) May 2028 (1) July 2028 (1) RC148 Phase 2 Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy Est. primary completion 2028-07 ·
NCT07895355 ·
CT.gov ↗ What to watch
December 2028 (2) Telitacicept Phase 3 Primary Sjogren's Disease Est. primary completion 2028-12 ·
NCT07404865 ·
CT.gov ↗ What to watch
RC28-E Phase 3 Diabetic Macular Edema (DME), wAMD Est. primary completion 2028-12-01 ·
NCT07936487 ·
CT.gov ↗ What to watch
2029 (5) March 2029 (1) Disitamab Vedotin Phase 1/2 High-risk Non-muscle Invasive Bladder Cancer Est. primary completion 2029-03-15 ·
NCT06378242 ·
CT.gov ↗ What to watch
May 2029 (1) June 2029 (1) July 2029 (1) Disitamab Vedotin Phase 2 Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms … Est. primary completion 2029-07-28 ·
NCT06157892 ·
CT.gov ↗ What to watch
December 2029 (1) RC148 Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2029-12 ·
NCT07756645 ·
CT.gov ↗ What to watch
2030 (1) April 2030 (1) RC148 Phase 2/3 Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Est. primary completion 2030-04-30 ·
NCT07935369 ·
CT.gov ↗ What to watch
2031 (1) April 2031 (1) RC148 Phase 3 Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations Est. primary completion 2031-04 ·
NCT07829549 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (11) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
July 2026 Withdrawal RC28-E RemeGen voluntarily withdraws the RC28-E DME application in China on NMPA review advice China, NMPA · RemeGen Co., Ltd. ·
Source ↗ 14 October 2025 Topline result Telitacicept Phase III Sjögren's Syndrome trial meets primary endpoint 30 September 2025 Topline result RC28-E DME Phase 3 vs aflibercept (NCT05885503) met its primary endpoint China · RemeGen Co., Ltd. and Santen Pharmaceutical Co., Ltd. ·
Source ↗ 30 September 2025 Filing accepted RC28-E China's CDE accepts the RC28-E BLA for diabetic macular edema China, NMPA · RemeGen Co., Ltd. and Santen Pharmaceutical Co., Ltd. ·
Source ↗ 19 September 2025 Filing accepted Telitacicept China BLA for Sjögren's Syndrome accepted by CDE 13 August 2025 Topline result Telitacicept China Phase 3 in primary Sjögren's (NCT05673993) met its primary endpoint 27 May 2025 Approval Telitacicept Telitacicept approved in China for generalized myasthenia gravis 12 May 2025 Topline result Disitamab Vedotin Phase 3 RC48-C016 meets PFS and OS primary endpoints 8 April 2025 Topline result Telitacicept China Phase 3 in generalized myasthenia gravis (NCT05737160): MG-ADL change -5.74 vs -0.91 with placebo at Week 24 October 2024 Filing accepted Disitamab Vedotin China BLA accepted for DV in HER2-positive breast cancer with liver metastasis October 2024 Priority review Disitamab Vedotin Priority review granted in China for DV in breast cancer with liver metastasis Financial reports Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $451M $170M $213M — report ↗
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $238M $214M — $205M report ↗